A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc.

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Bristol Myers Squibb (BMY) and Pfizer (PFE) announced a discount of over 40% on their blood thinner drug Eliquis when ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...

(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, ...

Pfizer is shaking up the cannabis light industry by bringing its global pharma muscle into play. The Cannabis Light Market is forecasted to grow 7.6% annually through 2030 thanks to big players like ...

Departures: Top Pfizer communications executive Sally Susman is stepping down, effective at the end of the year. Linda Yaccarino resigned as CEO of X. Miscellaneous: Six major medical groups, and a ...

The PUMP token launch introduces a dual-pool subscription model to accommodate users with varying needs: Exclusive Pool for New Users: Subscription Price: 0.0024 USDT (40% off market rate) ...